Xi'an Janssen, the pharmaceutical subsidiary of Johnson & Johnson in China, announced today that the State Food and Drug Administration has officially approved the use of Puzali in combination with other antiretroviral drugs to treat adult patients with human immunodeficiency vir

2024/06/1607:46:32 hotcomm 1286

China Net Finance, July 23 News Johnson & Johnson pharmaceutical subsidiary in China Xi'an Janssen announced today that the State Food and Drug Administration has officially approved the combined use of Puzali and other antiretroviral drugs to treat humans. Immunodeficiency virus (HIV)-infected adult patients.

According to reports, Puzeli consists of a fixed dose of the HIV protease inhibitor darunavir (800 mg) and the pharmacokinetics synergist cobicistat (150 mg). For the treatment of HIV infection, the current regimen is usually complex, and patients often need to take multiple drugs, with low compliance. Clinical data shows that Puzeli has proven efficacy and has a high resistance gene barrier, which will greatly improve patients' drug compliance .

A report by the Chinese Center for Disease Control and Prevention shows that reported cases of HIV infection in China are on the rise. In 2017, there were 134,512 newly reported cases of HIV infection/AIDS patients in China, which was a three-fold increase from the number of reported infection cases in 2006.

Xi'an Janssen, the pharmaceutical subsidiary of Johnson & Johnson in China, announced today that the State Food and Drug Administration has officially approved the use of Puzali in combination with other antiretroviral drugs to treat adult patients with human immunodeficiency vir - DayDayNews

hotcomm Category Latest News